In light of the worldwide COVID-19 pandemic, as well as rapid advances in technology in other areas of plasmid based medicines, vaccines, and gene therapies, a worldwide bottleneck has been created due to the plasmid DNA supply chain.
Four recent clinical research organization (CRO) acquisitions and mergers have indicated a growing trend among biotech manufacturing companies. Charles River acquired Cognate Bioservices, Catalent Paragon acquired Delphi, WuXi Advanced Therapies acquired Oxgene, and Wacker Biotech acquired Genopsis.
Nanoplasmid increases efficacy of DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus
Data from their ongoing Phase 1 expansion trial using Nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile.
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO™manufacturing platform.
As part of a new agreement with Nature Technology Corporation (NTC), Aegis Life and Entos will use NTC's proprietary Nanoplasmid™ plasmid DNA technology and manufacturing platform for the clinical and commercial production of their SARS-CoV-2 vaccine...
Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today will present data related to its proprietary manufacturing process designed to optimize its CAR-T product candidates. The Company will also illustrate the impact of these optimizations with preclinical data and preliminary clinical analysis with a focus on P-BCMA-101, its autologous CAR-T product candidate for multiple myeloma. The findings will be presented today at CAR-TCR Digital Week 2020 being held September 14-17, 2020.
Nature Technology Corporation, a leading developer and provider of non-viral vectors, technologies and services for advancing gene and cell therapy and immunotherapy, announced today that Deborah Moorad-Watts, formerly Chief Business Officer, has been appointed Chief Executive Officer of the Company....
